GAITHERSBURG, Md. — January 27, 2026 — Leads & Copy — BullFrog AI Holdings, Inc. has released a white paper, “Data Harmonization: The Hidden Prerequisite for Reliable AI/ML in Life Sciences,” discussing how the company’s bfPREPTM technology identifies patterns to transform biomedical data into harmonized formats.
The company (NASDAQ: BFRG; BFRGW) says its technology provides insights and analytical assets to assist in drug development.
BullFrog AI Founder and CEO Vin Singh said that many AI initiatives in biopharma drug development fail due to analysis reflecting data processing idiosyncrasies rather than biology.
The white paper explains how BullFrog AI makes biomedical data usable, with its team recognizing the state of the underlying data, which is often fragmented and trapped in formats that resist automated processing. The company’s bfPREPTM harmonizes and standardizes raw data into clean, analysis-ready datasets.
The white paper outlines where AI pipelines break in life sciences and presents a practical harmonization framework built on three pillars: engineering clinically meaningful derived features, producing reliable categorical variables and harmonized schemas, and transforming unstructured clinical documents into analysis-ready tables.
Singh said that the harmonization of data makes the value of AI and machine learning tangible and repeatable. He added that bfPREPTM, the first step in the company’s analytical toolkit, delivers reliable data sets to enable teams to spend less time wrangling with spreadsheets and more time interpreting results, designing studies, and making decisions.
The whitepaper is available for download.
BullFrog AI leverages AI and machine learning to advance drug discovery and development. The company uses causal AI in combination with its proprietary bfLEAP® platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials.
Source: BullFrog AI
